Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03FBV
|
|||
| Former ID |
DNCL001779
|
|||
| Drug Name |
PF-04950615
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Hypercholesterolaemia [ICD-11: 5C80.0] | Phase 3 | [1] | |
| Company |
Pfizer New York, NY
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Proprotein convertase subtilisin/kexin type 9 (PCSK9) | Target Info | . | [2] |
| WikiPathways | PCSK9-mediated LDLR degradation | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01975376) The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects. U.S. National Institutes of Health. | |||
| REF 2 | Phase 3 data for PCSK9 inhibitor wows. Nat Biotechnol. 2013 Dec;31(12):1057-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.